To assess the ability of combination treatment to eliminate primitive BCR-ABL+ cells with in vivo leukemia propagating activity, we utilized human BV173 cells, which have been shown to generate a lethal leukemia in NOD/SCID mice [22, 39]. The gene discussed is ABL1; the disease is leukemia.